Pancreatic Ductal Adenocarcinoma
266
82
121
58
Key Insights
Highlights
Success Rate
67% trial completion
Published Results
23 trials with published results (9%)
Research Maturity
58 completed trials (22% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
10.9%
29 terminated out of 266 trials
66.7%
-19.8% vs benchmark
5%
12 trials in Phase 3/4
40%
23 of 58 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 58 completed trials
Clinical Trials (266)
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Lead-212 PSV359 Therapy for Patients With Solid Tumors
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
WASH Trial: Intraoperative Lavage as a Treatment for Pancreatic Cancer
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
Fecal Microbial Transplants for the Treatment of Pancreatic Cancer
PHL Treatment in Pancreatic Cancer
Study for AZD4360 in Participants With Advanced Solid Tumours